Benign Prostatic Hyperplasia

Meet the patient

A 72-year-old man is sent up by his GP with six months of progressive nocturia — he is up four times a night — hesitancy, a stream that no longer arcs, and terminal dribbling that has begun to spot his trousers. He is otherwise well, on nothing but amlodipine, and his chief worry is that he "can't get a full night's sleep". A dipstick in the surgery was clear.[3]

Two questions decide this man's next two weeks, and they decide every BPH stem. First, is this BPH at all, or something dangerous hiding behind it? Acute retention, prostate cancer and a neurogenic bladder all wear LUTS as a disguise, and the DRE, the PSA and a focused history are what strip the disguise off. Second, if it is BPH, is this a medical problem or a surgical one? Severity, bother, prostate size and complications — not age alone — answer that. Hold those two questions and the rest of the page slots into place.[1][3]

LUTS is the symptom, BPH is the substrate

Modern urology keeps four words separate because the same man can wear each one independently, and conflating them is how patients get operated on for the wrong thing.[2]

• BPH — the histological finding: stromal and glandular hyperplasia of the transition zone, seen on biopsy or in resected chips.
• BPE (benign prostatic enlargement) — the clinical finding: an enlarged gland on DRE or imaging, volume over 30 mL.
• BPO (benign prostatic obstruction) — the urodynamic proof of raised urethral resistance on a pressure-flow study; a lab diagnosis, not a bedside one.
• LUTS — the symptom complex (voiding, storage, post-micturition), which may come from the prostate, the bladder, the urethra or the neurology, and often does not match the gland size at all.[2]

Etymology for viva gold: the prostate is named from the Greek proistanai — "one who stands before" — because the Alexandrian anatomists saw it standing guard at the bladder neck. And hyperplasia means more cells (not bigger cells — that is hypertrophy), which is the quiet reason the old exam term is technically a misnomer: the gland builds cells, it does not merely swell.[2]

BPH is not premalignant. It does not raise the risk of prostate cancer one iota. The two coexist in older men only because both are age-related, and they live in different postcodes: BPH in the transition zone, adenocarcinoma in the peripheral zone. A man with BPH carries the same age-related cancer risk as a man without — which is why DRE and PSA are mandatory in every man with LUTS, every time.[3]

[3]

IPSS grades the bother

The International Prostate Symptom Score turns a vague urinary complaint into a number that decides management, and every final-prof candidate must know the bands.[1]

[1]

The seven questions are incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each scored 0 (never) to 5 (almost always), totalling 0 to 35, with a single quality-of-life question bolted on — "If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel?" A QoL score of 4 or more (mostly dissatisfied to terrible) supports active treatment regardless of the symptom total, because bother, not the raw number, is what brings men to the clinic.[1]

Two further splits sit on top of the score and steer both the drug and the operation:[2]

• By prostate size — small (under 30 mL): an alpha-blocker may be all you need, and a 5-ARI adds little. Moderate (30 to 80 mL): alpha-blocker plus 5-ARI combination therapy. Large (over 80 to 100 mL): think HoLEP, ThuLEP or open simple prostatectomy, because monopolar TURP becomes long and difficult and TURP syndrome risk climbs.
• By phenotype — voiding-dominant (obstructive) leans on the alpha-blocker; storage-dominant (overactive bladder) adds an anticholinergic or beta-3 agonist only once the post-void residual is low and the obstruction addressed; mixed needs both, titrated to the dominant complaint.[2]

How common, and who is sitting in your clinic

BPH is age-related and androgen-dependent, and by the eighth decade it is almost universal — yet only a minority of histological BPH ever becomes the clinical disease you treat.[2]

Histological BPH appears in about 8 percent of men in their 30s, 50 percent of men aged 51 to 60, 70 percent in their 70s, and 80 to 90 percent of men over 80. But histology is not symptoms: about 25 to 50 percent of men with histological BPH develop clinically significant LUTS, and roughly 25 to 30 percent of men over 50 will eventually have some procedure for it in their lifetime. The gland you find at post-mortem is common; the man in your clinic with a blocked stream is the selected minority.[2]

The risk factors worth naming on a viva:[2]

• Age — the dominant factor; rare under 40, near-universal over 80.
• Androgens — BPH needs a working testis and dihydrotestosterone. Men castrated before puberty never develop it; androgen deprivation shrinks established disease.
• Family history — first-degree relatives of men having prostatectomy for BPH carry a four-fold risk of needing the same operation.
• Obesity and metabolic syndrome — visceral fat raises the oestrogen-to-androgen ratio and the inflammatory drive.
• Diabetes mellitus — through autonomic neuropathy hobbling the detrusor, and possibly direct prostatic effects.
• Sedentary lifestyle and ethnicity — physical activity is modestly protective; Black men tend to larger prostates and more severe symptoms, Asian men to lower rates that converge with westernisation.[2]

[2]

Two engines, two drugs — static compression and dynamic tone

The outlet narrows from two additive mechanisms, and memorising the duality is the whole of BPH pharmacology: one engine is mechanical, one is muscular, and each answers to a different drug.[2][5]

1. The static engine — the adenoma compresses the urethra. The hyperplastic transition zone physically narrows and elongates the prostatic urethra, and as it grows it can lift the bladder neck into a ball-valve at the internal meatus. This is the target of the 5-alpha-reductase inhibitors (finasteride, dutasteride), which block conversion of testosterone to DHT and shave 20 to 30 percent off prostate volume over 6 to 12 months.[2]

2. The dynamic engine — alpha-1 tone grips the bladder neck. The smooth muscle of the prostate stroma, bladder neck and prostatic urethra is densely wired with alpha-1 adrenergic receptors, mostly the alpha-1a subtype (about 70 percent of prostatic alpha-1 receptors). Background sympathetic tone holds it contracted, and any sympathetic surge — cold weather, stress, a pseudoephedrine cold remedy, anaesthesia — tightens the grip. This is the target of the alpha-1-blockers (tamsulosin, alfuzosin, doxazosin, terazosin, silodosin), which relax the muscle and drop urethral resistance within days.[2]

The hormonal engine under both. Testosterone is converted to dihydrotestosterone (DHT) by 5-alpha-reductase, which has two isoforms — type 1 (liver, skin, non-prostatic) and type 2 (prostate, genital skin). DHT drives stromal and epithelial proliferation. Finasteride blocks type 2 selectively (intraprostatic DHT down about 80 percent); dutasteride 0.5 mg OD blocks both (DHT down over 90 percent). The ageing testis makes less testosterone while peripheral aromatisation of androstenedione to oestrone raises the oestrogen-to-androgen ratio, sensitising the stroma to DHT — part of why BPH progresses with age.[2]

Left alone, the bladder decompensates in a predictable cascade — and this is the chain examiners love, because it links obstruction to every complication.[5]

[5]

LUTS decoded — voiding is obstruction, storage is the bladder complaining

Split LUTS into three groups and the mechanism, the drug choice and the differential all fall into line. Most men have a mixture, and the dominant phenotype steers the prescription.[1][3]

Voiding (obstructive) symptoms — the narrowed, high-resistance outlet speaking:[3]

• Hesitancy — the gap between arriving at the toilet and the start of flow; he waits or strains.
• Weak stream — reduced force and calibre; the stream no longer arcs.
• Straining to void — abdominal muscle (Valsalva) recruited to expel urine.
• Intermittency — the stream stops and starts within a single void.
• Terminal dribbling — a prolonged end-phase; drops fall on the footwear.
• Incomplete emptying — the sensation that urine remains after voiding.
• Prolonged voiding time — the whole act simply takes longer.[3]

Storage (irritative) symptoms — detrusor overactivity and falling compliance speaking:[3]

• Frequency — over 8 times a day is a useful flag.
• Urgency — a sudden, compelling need that is hard to defer.
• Nocturia — waking at night to void; the single most bothersome symptom and the strongest predictor of progression.
• Urge incontinence — leakage riding on the urgency.
• Dysuria — a burning sensation, usually flagging a superimposed UTI.[3]

Post-micturition: post-micturition dribble — a few drops leaking after he has left the toilet.[3]

The classic trap: never attribute new haematuria or new LUTS in an older man to "just his prostate" until you have done the DRE, checked the PSA, and excluded a bladder or prostate cancer. The friable vascularity of the hyperplastic transition zone can bleed, true — but so can a transitional-cell carcinoma at the bladder neck, and so can a peripheral-zone adenocarcinoma. Bleeding or a sudden change in pattern is cancer until a scope and a PSA say otherwise.[1][3]

BPH also presents through its complications rather than gradual LUTS, and these are the doors to the emergency take:[1]

• Acute urinary retention — sudden, painful inability to void with a tense, palpable bladder. Precipitants: anticholinergics, opioids, alpha-agonists (pseudoephedrine in cold remedies), alcohol, general or spinal anaesthesia, immobility after surgery, constipation.
• Chronic urinary retention — painless distension with overflow incontinence (constant dribbling from a full bladder); may declare itself insidiously as renal failure or as delirium in the elderly.
• Haematuria — usually painless, initial or total, from the friable transition-zone vascularity.
• Recurrent UTIs — residual urine is a culture medium.
• Bladder stones — forming in stagnant, infected urine.
• The atypical elderly presentation — confusion, falls, delirium, or being newly "wet" may be the first sign of retention or UTI on the background of BPH.[1]

Is this BPH, a stricture, or a neurogenic bladder?

Any cause of bladder outlet obstruction or LUTS can masquerade as BPH, and the differential matters because the operations diverge sharply — operating for BPH on a neurogenic bladder or a urethral stricture harms the patient and does not help the symptoms.[1][2]

[1] [2]

DRE first, always — and the consultant confession on the palpable bladder

The digital rectal examination is the single bedside act that must never be skipped in any man with LUTS — it is the fork between BPH and cancer, and it takes ten seconds. With the patient in the left lateral position, read the gland for size, surface, consistency, median sulcus, mobility and tenderness. BPH is smooth, rubbery and symmetrically enlarged with a preserved sulcus, like the tip of the nose; cancer is hard, irregular, craggy, with a lost sulcus, like a stone, and may be fixed to the pelvic sidewall. A boggy, exquisitely tender prostate is prostatitis, not BPH.[3]

Consultant confession — when to catheterise first: the man who rocks up to emergency with a palpable, tender, distended bladder and cannot void is in retention, and immediate management rests on timely bladder decompression by catheterisation — the Foley comes before the ultrasound. The catheter is both diagnostic and therapeutic in one act: the residual volume you drain confirms the diagnosis and treats it simultaneously. Reaching for imaging first, in a man writhing with a full bladder, is the recurring trainee move that delays decompression. Palpate, catheterise, then investigate.[21]

Beyond DRE: a palpable, dull, distended bladder means retention; ballotable kidneys suggest bilateral hydronephrosis from chronic high-pressure retention; suprapubic tenderness accompanies retention or UTI. Examine the genitals for phimosis or meatal stenosis (urethral causes), and check anal sphincter tone, perineal sensation and lower-limb reflexes to exclude a neurogenic bladder.[3]

The IPSS you score at the bedside is the same 7-item tool used in clinic — initial assessment, monitoring response, and deciding the threshold for intervention.[1]

Dipstick, U and E, PSA, and a bladder scan

The AUA and EAU agree on a small set of mandatory tests and a larger selective set, and the mandatory four are cheap, fast and decision-changing.[1][5]

Mandatory in every man with LUTS:[2]

• Urinalysis (dipstick) — exclude UTI (leucocytes, nitrites) and screen for bladder cancer and stones (persistent haematuria). The single most cost-effective test in the work-up.
• U and E, creatinine — exclude renal impairment from chronic obstruction. An elevated creatinine with bilateral hydronephrosis is post-renal AKI and a surgical emergency.
• PSA — over 4 ng/mL warrants cancer investigation (multiparametric MRI, then biopsy if indicated). BPH itself mildly elevates PSA in proportion to gland size. PSA falls on finasteride — roughly 40 percent over a year — so never read an unadjusted PSA in a man on a 5-ARI.[19]
• Renal and bladder ultrasound — read prostate size, post-void residual volume (PVR) (over 100 to 200 mL is significant), bladder wall thickness, trabeculation and diverticula, and upper-tract dilation (hydronephrosis from chronic obstruction).[2]

Selected patients only:[2]

• Uroflowmetry — void into a device that graphs flow against time. Peak flow (Qmax) under 10 mL/s suggests significant obstruction; under 4 mL/s is severe. The normal bell curve flattens and elongates as obstruction worsens.
• PVR by bladder scan — over 100 mL suggests incomplete emptying, over 200 to 300 mL flags decompensation and a higher risk of retention.
• Pressure-flow study (urodynamics) — the gold standard for diagnosing bladder outlet obstruction: a detrusor pressure over 40 cmH2O with a Qmax under 10 mL/s defines obstruction. Reserved for diagnostic uncertainty, young men, suspected detrusor underactivity, or prior failed prostate surgery.
• Flexible cystoscopy — visualises the bladder (trabeculation, stones, diverticula, tumours) and the prostatic urethra (lateral-lobe and median-lobe enlargement); essential before TURP and whenever haematuria is present.
• Transrectal ultrasound (TRUS) — measures prostate volume accurately and guides biopsy if cancer is suspected; not routine for uncomplicated BPH.
• Multiparametric prostate MRI — the modern standard for cancer work-up when PSA or DRE is suspicious.[5]

Catheterise first, decompress the kidney — the two emergencies

BPH becomes time-critical in exactly two scenarios: acute urinary retention, and chronic retention with renal failure. Both are decompression-first; the operation comes later, once the patient is safe.[1]

Acute urinary retention — the emergency:[1]

• Immediate urethral catheterisation — timely decompression is the whole of immediate management. The catheter is diagnostic and therapeutic in one act; record the residual volume drained.[21]
• If urethral catheterisation fails, do not force repeated traumatic attempts — know the routes and types of catheterisation, including a suprapubic catheter after confirming a palpable bladder, and step up rather than traumatise.[21]
• Check U and E — post-renal AKI from obstruction.
• Start an alpha-1-blocker (tamsulosin 0.4 mg OD) with the catheter in situ — the first-line drug while the bladder drains and a TWOC is planned.[12]
• Trial without catheter (TWOC): remove and observe whether he voids with a satisfactory PVR. If he voids, continue the alpha-blocker (add a 5-ARI if the prostate is enlarged); if he fails, re-catheterise and schedule definitive surgery (TURP or HoLEP).[21]

Chronic retention with renal impairment:[1]

• Catheterise (urethral or suprapubic) and watch for post-obstructive diuresis — urine output over 200 mL/h for 2 consecutive hours, or over 3 L in 24 h, after decompression. It is a physiological response to cleared obstruction, but it can cause hypovolaemia and electrolyte loss.
• Replace with IV 0.9% saline guided by urine output, checking sodium, potassium and creatinine every 6 to 12 hours and correcting electrolytes.
• Plan definitive surgery (TURP) once renal function and electrolytes stabilise; operating on uncorrected uraemia and hyperkalaemia risks arrhythmia and bleeding.[1]

The classic trap — alpha-blocker orthostatic hypotension in the elderly: the older non-selective agents (doxazosin, terazosin) are titrated for exactly this reason — PREDICT started doxazosin at 1 mg daily and stepped up to a maximum of 8 mg over about 10 weeks — and the same caution applies to any alpha-blocker in a man already on antihypertensives. Start low, warn him to rise slowly, and review the antihypertensive list before you add the prescription. A hip fracture from a first-dose faint is a wholly avoidable complication.[8]

Alpha-blocker fast, 5-alpha-reductase slow and only for big prostates

The medical ladder is conservative, then alpha-blocker, then add a 5-ARI for the enlarged gland — and the size of the prostate, not the symptom score alone, decides whether the second drug earns its place.[1][5]

Conservative (mild symptoms — IPSS 0 to 7, or as baseline for everyone):[1]

• Watchful waiting. Reassess IPSS, DRE and PSA annually. Many men never progress.
• Lifestyle: cut caffeine and alcohol (both bladder irritants and diuretics); limit evening fluids for nocturia; timed voiding every 2 to 3 hours; double voiding (void, wait, void again); treat constipation (straining worsens obstruction); review and stop bladder-aggravating drugs where possible (anticholinergics, opioids, evening diuretics).[1]

Medical (moderate to severe — IPSS 8 and above):[1]

1. Alpha-1-blockers — first-line for rapid relief. A network meta-analysis of 22 randomised trials (3371 patients, six alpha-blockers) confirms the class improves IPSS, flow and residual volume versus placebo, with tamsulosin 0.4 mg the best-ranked agent across IPSS, Qmax and PVR.[12]

   • Tamsulosin 0.4 mg OD — alpha-1a selective; the dose used across the landmark trials and the top-ranked agent for symptom score.[12]
   • Silodosin 8 mg OD — highly alpha-1a selective; improves symptom scores versus placebo with efficacy broadly matching tamsulosin in the Cochrane review of 19 trials.[13]
   • Doxazosin — non-selective and titrated: PREDICT started at 1 mg daily and stepped up to a maximum of 8 mg; start low to dodge first-dose hypotension.[8]
   • Onset rapid (days to weeks) — symptom scores separate from placebo within weeks, which is why the alpha-blocker owns the short clock while a 5-ARI is still loading.[12]
   • Side effects: ejaculatory dysfunction is the class signature — silodosin raised sexual adverse events about 26-fold versus placebo (and about 6-fold versus tamsulosin) in the Cochrane review — plus dizziness and cardiovascular effects.[13]
   • Floppy iris syndrome during cataract surgery — every alpha-1-blocker in this list (tamsulosin, alfuzosin, terazosin, doxazosin) is an established risk factor in a meta-analysis of 17 studies of phacoemulsification; tell the ophthalmologist before the list.[18]
   • They do not shrink the prostate — only relax muscle — so symptoms return on cessation.

2. 5-Alpha-reductase inhibitors — for the enlarged gland: prostate 30 mL or more, or PSA 1.5 to 10 ng/mL (the CombAT enrolment stratum).[7]

   • Finasteride 5 mg OD — inhibits type 2 5-alpha-reductase; the original 12-month trial cut prostate volume by about 19 percent and lifted Qmax by 22 percent.[10]
   • Dutasteride 0.5 mg OD — inhibits both isoforms; the dose used throughout the 4-year CombAT trial.[7]
   • Onset slow (months, not days) — volume falls over 6 to 12 months and the retention/surgery benefit accrues over years.[10]
   • Long-term benefit: in PLESS (3040 men, 4 years) finasteride cut the risk of acute retention by 57 percent and of BPH surgery by 55 percent versus placebo, and MTOPS confirmed that finasteride (but not doxazosin) reduces retention and invasive therapy.[9][4]
   • Side effects: decreased libido, impotence and ejaculatory disorders were significantly more frequent than placebo from the first finasteride trial onwards.[10]
   • PSA falls on a 5-ARI — roughly 40 percent over a year in a prospective series — so never read an unadjusted PSA in a man on finasteride.[19]

3. Combination therapy (alpha-blocker plus 5-ARI) — the strategy for the enlarged gland.[4]

   • Start both together: the alpha-blocker gives immediate relief while the 5-ARI works over months.

The 5-ARI threshold and the three trials that made combination therapy — MTOPS, PREDICT and CombAT

The 5-ARIs earn their place only when the gland is enlarged — the CombAT trial enrolled men with prostates of 30 mL or more and PSA 1.5 to 10 ng/mL — because a small gland has little hyperplastic substrate to shrink.[7] MTOPS (McConnell et al, NEJM 2003; 3047 men, mean follow-up 4.5 years) randomised men to doxazosin, finasteride, combination or placebo. Overall clinical progression fell 39 percent with doxazosin, 34 percent with finasteride and 66 percent with combination therapy versus placebo — the combination significantly beat either drug alone, and only finasteride and the combination (not doxazosin) cut the risks of acute retention and invasive therapy.[4] PREDICT (Kirby et al, 2003; 1095 men, 52 weeks) is the counterpoint that sharpens the teaching: doxazosin (titrated 1 to 8 mg) and the doxazosin-finasteride combination both beat placebo on IPSS and Qmax, while finasteride alone matched placebo over one year — on the short clock the alpha-blocker owns the symptom score, and the 5-ARI needs an enlarged gland and years to pay its way.[8] CombAT (Roehrborn et al; 4844 men, 4 years) confirmed the strategy with dutasteride 0.5 mg plus tamsulosin 0.4 mg in men with prostates of 30 mL or more: combination beat tamsulosin monotherapy on the risk of acute retention or BPH surgery, beat both monotherapies on clinical progression and symptoms, and delivered greater nocturia improvement than either drug alone sustained over the full 4 years.[7][6]

4. PDE5 inhibitors — when LUTS and erectile dysfunction ride together.[11]

   • Tadalafil 5 mg OD — in a 12-week randomised trial it improved IPSS by 5.6 points versus 3.6 with placebo, with the effect apparent within one week, and improved erectile function scores in parallel.[11]

5. Anticholinergics or beta-3 agonists — added for predominant storage symptoms.[20]

   • The randomised-trial strategy for overactive-bladder symptoms riding on BPH is to add mirabegron or an antimuscarinic to the alpha-blocker — the exact pairing is a network-meta-analysis question, but the add-on principle is settled.[20]
   • Reserve the add-on for men whose post-void residual is low and obstruction has been addressed — these drugs can precipitate retention in significant untreated obstruction.

6. Phytotherapy (saw palmetto, Pygeum africanum, beta-sitosterol).[2]

   • Widely self-prescribed, but a large NIH-funded trial showed no significant benefit over placebo. Treat it as placebo-equivalent and counsel accordingly.[2]

TURP is still the surgical standard

Surgery enters when medical therapy fails, is refused, or never had a chance — refractory retention, recurrent UTIs, bladder stones, refractory haematuria, renal impairment from obstruction, or severe refractory symptoms. The gold standard remains TURP, but the laser and minimally invasive options have eaten into its territory for the right patient.[1][5]

Indications for surgery:[1]

• Refractory retention (failed TWOC).
• Recurrent UTIs attributable to residual urine.
• Bladder stones.
• Persistent gross haematuria from BPH refractory to medical therapy.
• Renal impairment from obstruction (bilateral hydronephrosis, rising creatinine).
• Severe symptoms refractory to or intolerant of medical therapy.[1]

The procedures:[1][5]

1. TURP (transurethral resection of the prostate) — the gold standard.[5]

   • Spinal or general anaesthesia; lithotomy position. A resectoscope resects the transition-zone adenoma in chips with a diathermy loop, carving a wide channel from bladder neck to verumontanum.
   • Chips go to histology — incidental prostate cancer turns up in 5 to 10 percent (staged T1a or T1b).
   • Irrigation: non-electrolyte fluid (required for monopolar diathermy) — the source of TURP syndrome.
   • Post-op: 3-way Foley with continuous bladder irrigation for 24 to 48 hours; stay 2 to 4 days.
   • 85 to 90 percent symptom improvement.

2. Bipolar TURP (plasma-kinetic resection) — saline-based resection; the meta-analysis of 23 randomised trials shows efficacy and overall morbidity comparable to monopolar TURP, with a technique-specific complication profile.[14]

3. HoLEP (holmium laser enucleation of the prostate) — a holmium laser enucleates the adenoma along the surgical capsule (like peeling an orange from its skin) and a morcellator removes it. For very large prostates (over 100 mL): in a randomised trial of 120 such glands, HoLEP matched open prostatectomy at 5 years for symptom score, flow and reoperation (5 vs 6.7 percent) — a true endourological alternative. Meta-analysis places it with the transurethral options of comparable efficacy to TURP.[15][14]

4. GreenLight laser (PVP) — a KTP laser vaporises adenoma; photoselective vaporization is one of the technologies whose guideline statements were updated in the 2023 AUA amendment.[1]

5. ThuLEP (thulium laser enucleation) — laser enucleation in the technique family whose evidence the AUA amendment reviewed alongside HoLEP.[1]

6. Open or laparoscopic or robotic simple prostatectomy (retropubic Millin or suprapubic Freyer) — the traditional option for very large glands (over 100 g), enucleating the adenoma through the surgical capsule and leaving the peripheral zone intact. The randomised comparison shows HoLEP matches its 5-year outcomes, so it is increasingly replaced by endoscopic enucleation.[15]

7. Minimally invasive therapies (MISTs) — selected patients:[1]

   • UroLift (prostatic urethral lift): permanent implants hold the lateral lobes apart, opening the urethra without resection. In the randomised L.I.F.T. study (prostates 30 to 80 cc) erectile and ejaculatory function were preserved, with no de novo sustained sexual dysfunction at 5 years and 13.6 percent surgical retreatment.[16]
   • Rezum (water vapour thermal therapy): steam injections ablate transition-zone tissue; its AUA guideline statements were updated in the 2023 amendment.[1]
   • Prostatic artery embolisation (PAE): interventional radiology embolises the prostatic arteries; statements updated in the same amendment.[1]
   • Temporary implanted prostatic devices (TIPD): a new statement class added by the 2023 AUA amendment for selected patients.[1]

TURP syndrome in depth — the irrigation-fluid emergency

The most feared complication of monopolar TURP is systemic absorption of hypotonic irrigation fluid through open prostatic venous sinuses. TUR syndrome is generally defined as cardiovascular and/or neurological manifestations with serum sodium of 125 mmol/L or less; in a retrospective series of 229 resections, an operation time of 90 minutes or longer and continuous bladder drainage were independent risk factors for becoming symptomatic, and a fall in sodium over 7 mmol/L predicted clinical manifestations (sensitivity 0.72, specificity 0.87).[17] It presents intra- or early post-op with the cardiovascular and neurological features of acute dilutional hyponatraemia — confusion, nausea and deteriorating consciousness — and the deeper the sodium falls, the worse the neurological score.[17] Management: stop surgery, secure the airway, support the circulation, and treat the hyponatraemia — the same retrospective series gives you the trigger: watch the sodium change, because a drop beyond 7 mmol/L is the patient who is about to declare himself.[17] Prevention: respect the clock (90 minutes or more was an independent risk factor), and prefer bipolar TURP or laser enucleation, whose profiles the transurethral meta-analysis maps against TURP.[14]

Special situations that change the operation:[1]

• Acute retention: catheterise immediately (decompression is the emergency management), start tamsulosin 0.4 mg OD, check U and E, and plan a TWOC — a failed TWOC goes to theatre.[21][12]
• Chronic retention with renal impairment: catheterise, watch for post-obstructive diuresis, correct electrolytes, plan TURP once stable. Bilateral hydronephrosis with elevated creatinine is a surgical priority.
• Incidental prostate cancer in TURP chips: found in a minority of specimens — volume and grade at the urology MDT decide surveillance versus definitive treatment.
• Large prostate (over 100 mL): HoLEP or open simple prostatectomy over monopolar TURP — the randomised trial of glands over 100 g showed the two are equivalent, and both spare the patient a prolonged monopolar resection.[15]
• Anticoagulated patient: stop or bridge anticoagulation per protocol before any prostate surgery, and weigh the technique-specific bleeding profile of the alternatives against TURP.[14]

Named traps — the recurring trainee errors

Name these and you will not make them. Each is a mark-loser in the viva and a harm to the patient on the ward.[1]

• Skipping the DRE — the smooth rubbery gland of BPH and the hard craggy gland of cancer feel different for a reason; miss it and you miss the cancer.
• Forgetting the PSA, or not adjusting it for finasteride — the PSA falls substantially on a 5-ARI, so a "normal" reading on finasteride may be under-calling cancer.[19]
• Attributing new haematuria or new LUTS to "just BPH" — scope it and stage it; bladder cancer at the neck and prostate cancer both hide behind LUTS.
• Prescribing an alpha-blocker without warning about postural hypotension — first-dose faints and hip fractures in the elderly, especially with the non-selective agents and a loaded antihypertensive chart.
• Operating for BPH on a neurogenic bladder or a urethral stricture — surgery will not help and may harm; urodynamics before re-operation and in the young.
• Missing chronic retention with renal impairment — painless distension with a rising creatinine and bilateral hydronephrosis is a surgical priority, not a clinic follow-up.
• Not counselling retrograde ejaculation before TURP — it is the commonest post-op outcome and an avoidable source of dissatisfaction.[14]
• Performing monopolar TURP on a therapeutically anticoagulated patient — catastrophic bleeding; choose HoLEP, bipolar TURP, GreenLight or UroLift.[1][5]

Complications — by disease and by operation

BPH harms the patient directly, and so does its surgery; both lists are examinable, and the second is the one candidates forget.[1]

Complications of untreated BPH:[1]

• Acute urinary retention — the commonest emergency presentation.
• Chronic retention with overflow incontinence.
• Chronic renal failure from obstructive nephropathy (bilateral hydronephrosis, cortical thinning) — may be irreversible if decompression is delayed.
• Recurrent UTIs from residual urine.
• Bladder stones from stasis and infection.
• Recurrent gross haematuria from prostatic vascularity.
• Bladder decompensation — a flaccid, trabeculated, underactive detrusor that may never recover, even after the obstruction is lifted.[1]

TURP syndrome — the most feared complication (see the Reveal above for the full mechanism and management).[5]

Other complications of TURP:[1]

• Retrograde ejaculation — the commonest post-operative outcome; semen passes backward into the bladder at orgasm because the bladder neck has been resected open. Counsel pre-op; harmless but causes subfertility.[14]
• Urinary incontinence — 1 to 3 percent (stress or urge); usually temporary, may be permanent from external sphincter injury.
• Erectile dysfunction — 5 to 10 percent (controversial; may be pre-existing or unrelated).
• Urethral stricture or bladder neck contracture — 3 to 5 percent; presents weeks to months later with a worsening stream.
• Bleeding requiring transfusion — 2 to 5 percent.
• UTI or bacteraemia — 5 to 10 percent; prophylactic antibiotics reduce risk.
• Re-operation for recurrent obstruction — 5 to 10 percent at 10 years.[1]

[17]

Prognosis and disposition

Medical therapy controls symptoms but does not cure BPH — symptoms may progress, and adherence matters. The MTOPS trial showed combination therapy (doxazosin plus finasteride) reduced overall clinical progression by 66 percent versus placebo (doxazosin 39, finasteride 34), beating either alone; and in PLESS, finasteride cut the 4-year risk of acute retention by 57 percent and of BPH surgery by 55 percent versus placebo.[4][9]

TURP and its endoscopic alternatives deliver comparable, durable functional improvement — the meta-analysis of 23 randomised transurethral trials found equivalent efficacy and overall morbidity for MISTs versus contemporary TURP, with technique-specific complication profiles — and for the biggest glands the randomised comparison of HoLEP with open prostatectomy held up at 5 years.[14][15]

Untreated BPH in men with enlarged glands is progressive. In the placebo arm of PLESS, 7 percent developed acute urinary retention and 10 percent needed BPH surgery within four years, and the men CombAT enrolled — prostates of 30 mL or more, PSA 1.5 to 10, moderate-to-severe symptoms — are exactly the stratum the trials flag as progression-prone and the very patients who benefit from combination therapy.[9][7]

Disposition: stable medical-therapy patients are managed as outpatients with annual review (IPSS, DRE, PSA, PVR if indicated). Patients in retention are admitted for catheterisation, TWOC planning and often surgery. Those with renal impairment from chronic retention are admitted for decompression, electrolyte correction and definitive surgery once stabilised.[1]

Special populations

• The elderly: higher retention and complication risk; tamsulosin is safe and effective. Prefer HoLEP, GreenLight or bipolar TURP over monopolar TURP for the frail (less bleeding, shorter stay, no glycine). Watch the drug interactions — alpha-blockers plus antihypertensives cause postural hypotension and falls.[1]
• The anticoagulated patient: stop anticoagulation before TURP (bridge with LMWH if high thrombotic risk); prefer HoLEP, bipolar TURP, GreenLight or UroLift for superior haemostasis. Never perform monopolar TURP on a therapeutically anticoagulated patient.[1]
• Renal impairment from chronic retention: catheterise, correct renal function and electrolytes before elective surgery, and monitor for post-obstructive diuresis after decompression.[1]
• Concurrent prostate cancer: TURP may palliate obstruction in advanced cancer. Counsel the fertility implications of retrograde ejaculation with younger patients.[1]
• Younger men with LUTS: suspect bladder neck stenosis, prostatitis or a neurogenic bladder — urodynamics and cystoscopy before committing to BPH surgery; BPH severe enough to obstruct under 40 is rare.[5]
• Men on nitrates: tadalafil for BPH-LUTS is contraindicated with nitrates — profound hypotension.[1]

Evidence, guidelines and regional deltas

AUA Guidelines (2021 to 2026):[1][2][3]

• Alpha-blocker first-line for bothersome moderate-to-severe LUTS; tamsulosin 0.4 mg ranked best for IPSS, Qmax and PVR in the network meta-analysis.[12]
• 5-ARI for the enlarged gland — the CombAT stratum of prostate 30 mL or more or PSA 1.5 to 10 ng/mL — reduces volume and long-term progression.[7]
• Combination therapy (alpha-blocker plus 5-ARI) for larger prostates — the MTOPS 66 percent progression reduction, CombAT-confirmed.[4][7]
• Tadalafil 5 mg daily for men with concomitant LUTS and ED.[11]
• Anticholinergics or beta-3 agonists added to the alpha-blocker for storage symptoms when PVR is acceptable.[20]
• Surgery for refractory symptoms or complications (retention, stones, recurrent UTI, renal impairment, refractory haematuria).[21]
• HoLEP an evidence-based alternative to TURP for large glands.[15]
• MISTs (UroLift, Rezum) for selected patients prioritising sexual-function preservation.[16][1]

EAU Guidelines (Gratzke et al, 2015):[5]

• Mirror the AUA on alpha-blockers, 5-ARIs and combination therapy.
• Emphasise pressure-flow studies when obstruction is uncertain and before re-operation.
• Endorse HoLEP and laser techniques as size-independent alternatives to TURP.
• Highlight prostate volume and patient values (sexual function, anaesthetic risk, recovery) in procedural choice.[5]

What the landmark trials agree on (read these before the viva):[4][8][7] MTOPS gives the long-game progression case, PREDICT the short-game symptom case, and CombAT the enlarged-gland combination case — together they are the evidence spine of this whole page.

Landmark trials:[4][8][7]

• MTOPS (McConnell et al, NEJM 2003): combination doxazosin-finasteride reduced overall clinical progression by 66 percent versus placebo, beating doxazosin (39 percent) and finasteride (34 percent) alone; only finasteride and the combination cut retention and invasive therapy.[4]
• PREDICT (Kirby et al, 2003): at 52 weeks, doxazosin (titrated 1 to 8 mg) and doxazosin plus finasteride beat placebo on IPSS and Qmax, while finasteride alone did not — the alpha-blocker owns the symptom clock at one year.[8]
• CombAT (Roehrborn et al, 2010): dutasteride 0.5 mg plus tamsulosin 0.4 mg for 4 years in prostates of 30 mL or more beat tamsulosin monotherapy on acute retention or BPH surgery, and beat both monotherapies on progression, symptoms and nocturia.[7][6]

[5]

Exam pearls

• Transition zone is BPH. Peripheral zone is prostate cancer. Different zones, different diseases. BPH is not premalignant.[2]
• DRE: BPH is smooth, rubbery, symmetrically enlarged, preserved sulcus. Cancer is hard, irregular, craggy, lost sulcus. Always do DRE.[3]
• IPSS: 0 to 7 mild, 8 to 19 moderate, 20 to 35 severe. Drives management; the QoL question captures bother.[1]
• Tamsulosin is alpha-1a selective, rapid (days to weeks), and does NOT shrink the prostate. Counsel floppy iris syndrome — tell the ophthalmologist before cataract surgery.[12][18]
• Finasteride is a 5-ARI (type 2), blocks DHT, cut prostate volume by about 19 percent at 12 months, and lowered PSA by roughly 40 percent over a year — never read an unadjusted PSA on a 5-ARI. Side effects: reduced libido, impotence, ejaculatory disorders.[10][19]
• Combination therapy (alpha-blocker plus 5-ARI) beats either alone for the prostate over 30 mL — MTOPS, 66 percent progression reduction; CombAT confirmed with dutasteride plus tamsulosin.[4][7]
• TURP is the gold standard. Non-electrolyte irrigation for monopolar diathermy. Retrograde ejaculation is the commonest post-op outcome — counsel pre-op.[14]
• TURP syndrome is dilutional hyponatraemia from irrigation-fluid absorption: cardiovascular and neurological manifestations with sodium 125 mmol/L or less; resection 90 minutes or longer is a risk factor and a sodium fall over 7 mmol/L predicts who becomes symptomatic. Prevent by limiting resection time or using bipolar TURP or HoLEP.[17]
• Acute retention is catheterise immediately (decompression is the emergency management), then tamsulosin and a TWOC. A failed TWOC or recurrent retention is surgery.[21][12]
• PSA over 4 ng/mL warrants cancer investigation. PSA falls roughly 40 percent on finasteride — never read it unadjusted.[19]
• Qmax under 10 mL/s suggests obstruction; PVR over 100 to 200 mL suggests decompensation. The pressure-flow study is the gold standard for bladder outlet obstruction.[2]
• UroLift preserved erectile and ejaculatory function at 5 years in the randomised L.I.F.T. study (prostates 30 to 80 cc) — for selected patients prioritising sexual function.[16]

The mantra, and the mnemonic

[3]

The mantra: LUTS is the symptom, BPH is the substrate; alpha-blocker fast, 5-ARI slow and only for the big gland; catheterise the palpable bladder first.[1][2]

Ward-round test — three stems

Stem 1 — acute retention in a 74-year-old (answer)

A 74-year-old man presents at 2 am with sudden inability to void and severe suprapubic pain; his bladder is palpable and dull to percussion. Outline the first-hour work-up and the decision pathway. Model: This is acute urinary retention — the immediate move is urethral catheterisation, which is both diagnostic and therapeutic; record the residual drained. Timely decompression is the whole of immediate management. Check U and E for post-renal AKI, start tamsulosin 0.4 mg OD, and treat any precipitant (constipation, an anticholinergic, post-op immobility). Plan a trial without catheter; if he fails, re-catheterise and list him for TURP or HoLEP. If the gland is hard or craggy or the PSA is elevated, work up cancer before resecting.[21][12]

Stem 2 — haematuria plus new LUTS in a 68-year-old (answer)

A 68-year-old reports painless gross haematuria throughout the stream and three months of new nocturia and hesitancy. His GP called it "his prostate". What must you do before accepting that diagnosis? Model: Never attribute new haematuria or new LUTS to BPH until cancer is excluded. Do a DRE — a hard, irregular, craggy gland with a lost sulcus is prostate cancer until proven otherwise; a smooth rubbery gland supports BPH but does not exclude a bladder-neck or peripheral-zone tumour. Check PSA (over 4 ng/mL warrants multiparametric MRI and biopsy), urinalysis and urine cytology. Perform a flexible cystoscopy to look for a bladder tumour (especially at the neck, which obstructs and bleeds) and to grade prostatic enlargement, and image the upper tracts (renal ultrasound or CT urogram). Only when cancer is excluded on DRE, PSA, scope and imaging may you attribute the bleeding to the friable BPH vascularity and treat the obstruction.[1][3]

Stem 3 — the man on finasteride with a 'normal' PSA (answer)

A 72-year-old on finasteride 5 mg OD for two years has a PSA of 2.1 ng/mL and an IPSS of 16. His DRE is smooth and rubbery. Is his prostate cancer risk excluded, and what is your next step? Model: Not yet. Finasteride lowers PSA — roughly 40 percent over a year in a prospective series — so a measured 2.1 understates his true level: never read an unadjusted PSA in a man on a 5-ARI, or you will under-call cancer. Treat the finasteride-adjusted value as the number that decides investigation; weigh it with the IPSS trend and the smooth DRE (reassuring for cancer) and discuss a multiparametric prostate MRI. Continue the finasteride for the moderate LUTS (it is working — the IPSS is moderate, not severe), add or continue an alpha-blocker if he is bothered, and reassure him that BPH is not premalignant — but the finasteride-adjusted PSA is the number you act on.[19][2]

References

1. [1]Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 J Urol, 2024.PMID 37706750
2. [2]Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management J Urol, 2021.PMID 34384237
3. [3]Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation J Urol, 2026.PMID 42095481
4. [4]McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med, 2003.PMID 14681504
5. [5]Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction Eur Urol, 2015.PMID 25613154
6. [6]Oelke M, Roehrborn CG, Wilson TH, et al. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study World J Urol, 2014.PMID 24804842
7. [7]Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol, 2010.PMID 19825505
8. [8]Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology, 2003.PMID 12559281
9. [9]McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia N Engl J Med, 1998.PMID 9475762
10. [10]Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia N Engl J Med, 1992.PMID 1383816
11. [11]Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial Eur Urol, 2011.PMID 21871706
12. [12]Yoosuf BT, Panda AK, Kt MF, et al. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis Sci Rep, 2024.PMID 38750153
13. [13]Jung JH, Kim J, MacDonald R, et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia Cochrane Database Syst Rev, 2017.PMID 29161773
14. [14]Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement Eur Urol, 2010.PMID 20825758
15. [15]Kuntz RM, Lehrich K, Ahyai SA Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial Eur Urol, 2008.PMID 17869409
16. [16]Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study Can J Urol, 2017.PMID 28646935
17. [17]Ishio J, Nakahira J, Sawai T, et al. Change in serum sodium level predicts clinical manifestations of transurethral resection syndrome: a retrospective review BMC Anesthesiol, 2015.PMID 25927332
18. [18]Chatziralli IP, Sergentanis TN Risk factors for intraoperative floppy iris syndrome: a meta-analysis Ophthalmology, 2011.PMID 21168223
19. [19]Xu D, Ding J, Zhu Y, et al. The new insight of prostate-specific antigen reduction during finasteride therapy in aging men Aging Clin Exp Res, 2016.PMID 26754047
20. [20]Herschorn S, Tarcan T, Jiang YH, et al. Safety and efficacy of an alpha-1-blocker plus mirabegron compared with an alpha-1-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis Neurourol Urodyn, 2024.PMID 38291827
21. [21]Mavrotas J, Gandhi A, Kalogianni V, et al. Acute urinary retention Br J Hosp Med (Lond), 2022.PMID 35129387